In 2023 we saw several successful funding rounds for iPSC-centric biotechnology companies, with Kenai Therapeutics and Shinobi Therapeutics both raising over $50 million in Series A Funding.

With indications like autoimmune conditions and solid tumors receiving increasing attention it feels like the next wave of investment into stem cell medicines is imminent, and our partners recognize the importance of showcasing their services and expertise ahead of this boom.

For the first time in 4-years, we are united both R&D teams and manufacturing development teams for 3-days of industry-lead presentations and cross-functional discussions looking to overcome the current bottlenecks for wide-spread usage of iPSCs in regenerative medicine and beyond.